BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertensionBusiness Wire • 05/18/26
AstraZeneca wins US approval for first-in-class blood pressure drug and expands cancer treatment EnhertuProactive Investors • 05/18/26
AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trialReuters • 05/14/26
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZenecaBusiness Wire • 05/13/26
BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026Accesswire • 05/12/26
6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash24/7 Wall Street • 05/06/26
AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate FaltersBenzinga • 05/01/26
Citi raises AstraZeneca earnings forecast and maintains 'buy' rating ahead of second-half pipeline catalystsProactive Investors • 04/30/26
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZenecaPRNewsWire • 04/29/26
Astrazeneca (AZN) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 04/29/26